Vishwanath Ramatenki

Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach

Rohini Rondla, Lavanya Souda Padmarao, Vishwanath Ramatenki et al. · Computational Biology and Chemistry · 2017 · 29 citations

Molecular Recognition, Drug Target, Biochemistry +10

Homology modeling and virtual screening of ubiquitin conjugation enzyme E2A for designing a novel selective antagonist against cancer

Vishwanath Ramatenki, Sarita Rajender Potlapally, Rama Krishna Dumpati et al. · Journal of Receptors and Signal Transduction · 2014 · 28 citations · Full text

Drug Target, Engineering, Novel Selective Antagonist +21

Homology modeling and virtual screening studies of FGF-7 protein—a structure-based approach to design new molecules against tumor angiogenesis

Rajender Vadija, Kiran Kumar Mustyala, Navaneetha Nambigari et al. · Journal of Chemical Biology · 2016 · 20 citations · Full text

Tumor Biology, Angiogenesis, Medicine +12

Azolium analogues as CDK4 inhibitors: Pharmacophore modeling, 3D QSAR study and new lead drug discovery

Rohini Rondla, Lavanya Rao, Vishwanath Ramatenki et al. · Journal of Molecular Structure · 2017 · 17 citations

Medicinal Chemistry, Drug Target, Natural Sciences +11

Identification of New Lead Molecules Against UBE2NL Enzyme for Cancer Therapy

Vishwanath Ramatenki, Ramakrishna Dumpati, Rajender Vadija et al. · Applied Biochemistry and Biotechnology · 2017 · 14 citations

Cancer Therapy, Hit Identification, Biochemistry +6